MX2020009464A - Inmunoterapia de células t dirigidas por zetacina, direccionada al receptor alfa 2 de il-13. - Google Patents
Inmunoterapia de células t dirigidas por zetacina, direccionada al receptor alfa 2 de il-13.Info
- Publication number
- MX2020009464A MX2020009464A MX2020009464A MX2020009464A MX2020009464A MX 2020009464 A MX2020009464 A MX 2020009464A MX 2020009464 A MX2020009464 A MX 2020009464A MX 2020009464 A MX2020009464 A MX 2020009464A MX 2020009464 A MX2020009464 A MX 2020009464A
- Authority
- MX
- Mexico
- Prior art keywords
- targeted
- receptor alpha
- directed
- zetakine
- cell immunotherapy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5437—IL-13
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0026—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
- C12N9/0028—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with NAD or NADP as acceptor (1.5.1)
- C12N9/003—Dihydrofolate reductase [DHFR] (1.5.1.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y105/00—Oxidoreductases acting on the CH-NH group of donors (1.5)
- C12Y105/01—Oxidoreductases acting on the CH-NH group of donors (1.5) with NAD+ or NADP+ as acceptor (1.5.1)
- C12Y105/01003—Dihydrofolate reductase (1.5.1.3)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862643139P | 2018-03-14 | 2018-03-14 | |
| PCT/US2019/021833 WO2019178085A1 (en) | 2018-03-14 | 2019-03-12 | Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020009464A true MX2020009464A (es) | 2021-01-15 |
Family
ID=67907266
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020009464A MX2020009464A (es) | 2018-03-14 | 2019-03-12 | Inmunoterapia de células t dirigidas por zetacina, direccionada al receptor alfa 2 de il-13. |
| MX2025010440A MX2025010440A (es) | 2018-03-14 | 2020-09-10 | Inmunoterapia de celulas t dirigidas por zetacina, direccionada al receptor alfa 2 de il-13 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025010440A MX2025010440A (es) | 2018-03-14 | 2020-09-10 | Inmunoterapia de celulas t dirigidas por zetacina, direccionada al receptor alfa 2 de il-13 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12606603B2 (https=) |
| EP (2) | EP4491718A3 (https=) |
| JP (2) | JP7314161B2 (https=) |
| KR (2) | KR102917671B1 (https=) |
| CN (1) | CN112088165A (https=) |
| AU (2) | AU2019234580B2 (https=) |
| BR (1) | BR112020018534A2 (https=) |
| CA (1) | CA3093791A1 (https=) |
| EA (1) | EA202091984A1 (https=) |
| IL (1) | IL277268A (https=) |
| MX (2) | MX2020009464A (https=) |
| SG (1) | SG11202008926RA (https=) |
| WO (1) | WO2019178085A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3765041A4 (en) | 2018-03-14 | 2021-12-22 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | IL-13 CHIMERIC RECEPTOR ALPHA 2 (IL13RA2) ANTIGEN RECEPTOR FOR T-CELL T-CELL IMMUNOTHERAPY |
| EP4577575A1 (en) * | 2022-08-25 | 2025-07-02 | Nanjing Legend Biotech Co., Ltd. | Chimeric antigen receptors targeting interleukin 13 receptor subunit alpha 2 and methods of use thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090257994A1 (en) * | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US20090098142A1 (en) * | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| BRPI0819598A2 (pt) | 2007-11-30 | 2017-05-09 | Kalobios Pharmaceuticals Inc | anticorpos para o antígeno pcrv da pseudomonas aeruginosa |
| EP2331566B1 (en) | 2008-08-26 | 2015-10-07 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| TR201904484T4 (tr) | 2009-11-03 | 2019-05-21 | Hope City | Transdüse T hücre seçimine yönelik kesik epiderimal büyüme faktörü reseptörü (EGFRt). |
| CA2861491C (en) | 2012-02-13 | 2020-08-25 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| BR122020002986A8 (pt) | 2012-08-20 | 2023-04-18 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Método e composições para imunoterapia celular |
| KR101763499B1 (ko) | 2012-11-07 | 2017-07-31 | 화이자 인코포레이티드 | 항-il-13 수용체 알파 2 항체 및 항체-약물 접합체 |
| US9758807B2 (en) | 2012-12-05 | 2017-09-12 | SOLA Biosciences, LLC | Protein expression enhancing polypeptides |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| EP3783098A1 (en) | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| TWI751102B (zh) | 2014-08-28 | 2022-01-01 | 美商奇諾治療有限公司 | 對ｃｄ１９具專一性之抗體及嵌合抗原受體 |
| BR112017005631A2 (pt) | 2014-09-19 | 2018-06-26 | City Of Hope | células t com receptor de antígeno coestimulador quimérico direcionadas à il13ra2 |
| CN107683289B (zh) | 2015-01-26 | 2021-08-06 | 芝加哥大学 | IL13Rα2结合剂和其在癌症治疗中的用途 |
| CA2992989A1 (en) | 2015-07-21 | 2017-01-26 | City Of Hope | T cells for expression of chimeric antigen receptors and other receptors |
| WO2017040930A2 (en) * | 2015-09-03 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Biomarkers predictive of cytokine release syndrome |
| IL287889B2 (en) * | 2016-02-05 | 2024-03-01 | Hope City | Administration of engineered t cells for treatment of cancers in the central nervous system |
| KR20230148844A (ko) | 2016-03-29 | 2023-10-25 | 유니버시티 오브 써던 캘리포니아 | 암을 표적하는 키메라 항원 수용체 |
| MX2018014950A (es) | 2016-06-07 | 2019-04-25 | Macrogenics Inc | Terapia de combinacion. |
| US12304935B2 (en) * | 2016-07-29 | 2025-05-20 | Juno Therapeutics, Inc. | Immunomodulatory polypeptides and related compositions and methods |
| AU2017319702B2 (en) | 2016-09-02 | 2024-11-14 | The Regents Of The University Of California | Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments |
| US12083148B2 (en) | 2017-02-22 | 2024-09-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | IL13Ra2-binding chimeric antigen receptors |
| EP3765041A4 (en) | 2018-03-14 | 2021-12-22 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | IL-13 CHIMERIC RECEPTOR ALPHA 2 (IL13RA2) ANTIGEN RECEPTOR FOR T-CELL T-CELL IMMUNOTHERAPY |
-
2019
- 2019-03-12 EA EA202091984A patent/EA202091984A1/ru unknown
- 2019-03-12 JP JP2020549002A patent/JP7314161B2/ja active Active
- 2019-03-12 CA CA3093791A patent/CA3093791A1/en active Pending
- 2019-03-12 WO PCT/US2019/021833 patent/WO2019178085A1/en not_active Ceased
- 2019-03-12 MX MX2020009464A patent/MX2020009464A/es unknown
- 2019-03-12 US US16/979,475 patent/US12606603B2/en active Active
- 2019-03-12 AU AU2019234580A patent/AU2019234580B2/en active Active
- 2019-03-12 CN CN201980030021.9A patent/CN112088165A/zh active Pending
- 2019-03-12 BR BR112020018534-5A patent/BR112020018534A2/pt not_active Application Discontinuation
- 2019-03-12 KR KR1020207028968A patent/KR102917671B1/ko active Active
- 2019-03-12 KR KR1020267001996A patent/KR20260021083A/ko active Pending
- 2019-03-12 SG SG11202008926RA patent/SG11202008926RA/en unknown
- 2019-03-12 EP EP24214241.2A patent/EP4491718A3/en active Pending
- 2019-03-12 EP EP19767433.6A patent/EP3765487A4/en not_active Withdrawn
-
2020
- 2020-09-10 MX MX2025010440A patent/MX2025010440A/es unknown
- 2020-09-10 IL IL277268A patent/IL277268A/en unknown
-
2023
- 2023-07-12 JP JP2023114641A patent/JP7696958B2/ja active Active
-
2024
- 2024-04-24 AU AU2024202681A patent/AU2024202681A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020018534A2 (pt) | 2020-12-29 |
| EP3765487A1 (en) | 2021-01-20 |
| CN112088165A (zh) | 2020-12-15 |
| SG11202008926RA (en) | 2020-10-29 |
| AU2019234580A1 (en) | 2020-10-08 |
| JP2021518111A (ja) | 2021-08-02 |
| JP2023134631A (ja) | 2023-09-27 |
| US12606603B2 (en) | 2026-04-21 |
| US20210017246A1 (en) | 2021-01-21 |
| WO2019178085A1 (en) | 2019-09-19 |
| CA3093791A1 (en) | 2019-09-19 |
| KR20200131851A (ko) | 2020-11-24 |
| EA202091984A1 (ru) | 2021-02-18 |
| EP4491718A2 (en) | 2025-01-15 |
| IL277268A (en) | 2020-10-29 |
| EP3765487A4 (en) | 2022-01-05 |
| JP7696958B2 (ja) | 2025-06-23 |
| EP4491718A3 (en) | 2025-03-26 |
| MX2025010440A (es) | 2025-10-01 |
| KR102917671B1 (ko) | 2026-01-27 |
| AU2019234580B2 (en) | 2024-02-01 |
| JP7314161B2 (ja) | 2023-07-25 |
| AU2024202681A1 (en) | 2024-05-16 |
| KR20260021083A (ko) | 2026-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021001779A1 (es) | Polipéptidos que comprenden polipéptidos con il-2 modificada y usos de los mismos | |
| MX2020001490A (es) | Metodos para producir composiciones de celulas geneticamente modificadas y composiciones relacionadas. | |
| CO2019011450A2 (es) | Expresión transgénica selectiva de tejidos | |
| CO2017000507A2 (es) | Receptor quimérico de antígeno bcma | |
| PL3737765T3 (pl) | Komórki układu odpornościowego wzmocnione z użyciem podwójnego shrna i kompozycja zawierająca te komórki | |
| CO2017001573A2 (es) | Receptor quimérico de antígeno anti-cd123 | |
| BR112013005145A2 (pt) | anticorpos anti-cxcl13 e métodos para seu uso | |
| MX2020009309A (es) | Composiciones de cartirina y métodos para su uso. | |
| EA202091333A1 (ru) | Способы активации, модификации и экспансии t-клеток для лечения рака и связанных с ним злокачественных заболеваний | |
| CL2018001198A1 (es) | Métodos y composiciones para edición génica en hemocitoblastos | |
| MX2019010972A (es) | Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos. | |
| CL2022001622A1 (es) | Agentes de unión a ilt3 y métodos de uso de los mismos | |
| CL2018000101A1 (es) | Anticuerpos dirigidos contra il-33 y sus usos (divisional de la solicitud 201502469) | |
| EP4527922A3 (en) | Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof | |
| MX2020009463A (es) | Receptor de antígeno quimérico de receptor de il-13 alfa 2 (il13ra2) para inmunoterapia de células t específica para tumor. | |
| MX2015010836A (es) | Tratamiento de cancer utilizando un receptor quimerico de antigeno anti egfrviii humanizado. | |
| MY189819A (en) | Genetically modified cells and uses thereof | |
| MX2017001008A (es) | Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33. | |
| MX2016010345A (es) | Celulas para inmunoterapia diseñadas para dirigir antigeno presente tanto en celulas inmunes y celulas patologicas. | |
| BR112015030972A8 (pt) | células sc-beta e composições e métodos para geração das mesmas | |
| MX2017007293A (es) | Animales no humanos que tienen un gen del grupo de diferenciacion 47 humanizado. | |
| MX2020005849A (es) | Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos. | |
| BR112014006176A8 (pt) | Rna transcrito in vitro ou rna sintético, composição, método para gerar uma população de células t geneticamente modificadas por rna, e, uso de uma célula t geneticamente modificada | |
| BR112017000939A2 (pt) | tratamento de câncer usando um receptor antigênico quimérico de cll-1 | |
| BR112022009290A2 (pt) | Terapia para malignidades de células hematopoiéticas com o uso de células t geneticamente modificadas visando cd70 |